AI in Medicine: Advances, Analysis & Predictions (May 29, 2026)
Date: 2026-05-29 Status: Initial Edition Next Update: TBD Executive Summary Artificial Intelligence is transforming medicine at an accelerating pace. What was once confined to research labs and pilot studies is now becoming clinically deployed, FDA-cleared, and patient-facing. From AlphaFold 3’s atom-level biology simulations to AI copilots integrated into hospital EHR systems, the landscape in mid-2026 is markedly more mature than even 12 months prior. Key themes emerging: From diagnosis to prediction — AI is shifting from reactive diagnostics to proactive, predictive healthcare Multimodal AI — Models that combine text, imaging, genomics, and wearable data are outperforming single-modality systems Democratisation — Open-source models (DeepSeek, Qwen, Llama) are being fine-tuned for medical use, reducing costs Regulatory maturation — FDA clearance pathways for AI/ML-based SaMD (Software as a Medical Device) are now established Patient-facing AI — Major platforms (ChatGPT Health, Microsoft Copilot Health, Perplexity Health) now directly serve patients Domain 1: Drug Discovery & Development 1.1 AlphaFold 3 & Protein Biology DeepMind’s AlphaFold 3 (released 2024) represented a leap beyond previous iterations by modelling protein interactions with DNA, RNA, and small molecules — not just protein folding alone. By mid-2026, AlphaFold 3 has been integrated into pharmaceutical R&D pipelines at nearly every major drug company. ...